Takeda And Orexigen Make Deal For Diet Pill : Shots - Health News The companies would work together on selling Contrave, an experimental diet pill now under review by the Food and Drug Administration.
NPR logo Takeda And Orexigen Make Deal For Diet Pill

Takeda And Orexigen Make Deal For Diet Pill

Well, we didn't think today was going to be all-diet-pills-all-the-time, but here we are with another post on the subject.

Japanese drug giant Takeda and San Diego-based Orexigen have struck a marketing partnership to sell Contrave, an experimental weight-loss pill Orexigen has submitted to the Food and Drug Administration for approval.

The medicine combines bupropion, a drug most often used as an antidepressant, with naltrexone, a medicine used mainly for addiction.

Under terms of the Takeda deal, Orexigen is getting $50 million right away. Eventually the company could get more than $1 billion from Takeda, if everything goes well with the FDA and on the market.

That's not guaranteed. In July, a panel of experts advised the FDA not to approve Qnexa, a rival diet pill, because of concerns about risk.

Indeed, a recent nationwide survey done for NPR found that Americans are leery of weight loss medicines. Cost and side effects are turnoffs for many people. About a quarter of people surveyed said a successful drug would have to help them lose between about 20 and 30 pounds. A similar proportion said about 10 to 20 pounds would be enough.

Data from Orexigen studies showed that people who completed a year of treatment with Contrave lost an average of 17 1/2 lbs, or more than 8 percent of their weight.

The FDA is expected to make a decision on Contrave early next year.